Participants 0 137 8
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
Participants 286 310 6
advanced cancer patients
Participants 411 490 7
we measured 12-h ambulatory BP in 41 normotensive advanced solid tumor patients
Participants 1039 1130 5
gs in normotensive patients suggest BP is a complex pharmacodynamic biomarker of VEGF inhib
Participants 1131 1217 3
tion. Patients have intrinsic differences in sensitivity to sorafenib's BP-elevating e
